Combined GADD45A and thymidine phosphorylase expression levels predict response and survival of neoadjuvant-treated gastric cancer patients.

Napieralski, Rudolf

Combined GADD45A and thymidine phosphorylase expression levels predict response and survival of neoadjuvant-treated gastric cancer patients. [electronic resource] - Clinical cancer research : an official journal of the American Association for Cancer Research Apr 2005 - 3025-31 p. digital

Publication Type: Clinical Trial; Comparative Study; Journal Article; Research Support, Non-U.S. Gov't

1078-0432

10.1158/1078-0432.CCR-04-1605 doi


Adult
Aged
Antigens, Nuclear--genetics
Antineoplastic Combined Chemotherapy Protocols--therapeutic use
Cell Cycle Proteins--genetics
Cisplatin--administration & dosage
DNA-Binding Proteins--genetics
Dihydrouracil Dehydrogenase (NADP)--genetics
Endonucleases--genetics
Female
Fluorouracil--administration & dosage
Gene Expression Regulation, Neoplastic--drug effects
Humans
Ku Autoantigen
Male
Middle Aged
Neoadjuvant Therapy
Nuclear Proteins--genetics
Predictive Value of Tests
Prognosis
RNA, Messenger--genetics
Reverse Transcriptase Polymerase Chain Reaction--methods
Stomach Neoplasms--drug therapy
Survival Analysis
Thymidine Phosphorylase--genetics
Thymidylate Synthase--genetics
Treatment Outcome